Non-Alcoholic Fatty Liver Disease in Patients with Non-Metabolic Syndrome

Objective & Hypothesis:Aim: Non-alcoholic fatty liver disease (NAFLD) is the most common type of chronic liver diseases and it is the hepatic evidence of metabolic syndrome (MetS).

📊

Key Findings & Data:Material and Methods: Our study was made at least 400 volunteers from 10 randomly selected Family Health Centers (FHCs) in our city center.

💡

Conclusion & Impact:In multivariate logistic regression analysis, BMI (OR: 1.311, p

🔬Design:Modeling & Simulation

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Aim: Non-alcoholic fatty liver disease (NAFLD) is the most common type of chronic liver diseases and it is the hepatic evidence of metabolic syndrome (MetS). But patients with NAFLD have not always MetS, and all patients with MetS have not always NAFLD. In our study, we aimed to investigate the factors related to NAFLD in patients with non-MetS. Material and Methods: Our study was made at least 400 volunteers from 10 randomly selected Family Health Centers (FHCs) in our city center. Complete blood counts, biochemical tests and hepatobiliary ultrasonography (hUSG) were performed from the individuals. Body mass index (BMI), homeostasis Model Assessment of insulin Resistance (HOMA-IR), fibrosis-4 (FIB-4) and BARD scores were calculated. Results: The prevalence of fatty liver was detected as 33.8% with hUSG. The frequencies of stage 1, 2 and 3 fatty liver were found to be 71.6%, 25.4% and 3.0%, respectively, in those with fatty liver (n=67). In univariate analysis; there were statistically significant differences between those with and without fatty liver individuals for the parameters of age, BMI, waist circumference, diastolic blood pressure, hemoglobin, AST/ALT ratio, ALT, GGT and triglyceride levels. In multivariate logistic regression analysis, BMI (OR: 1.311, p

Özet

Amaç: Non-alkolik yağlı karaciğer hastalığı (NAYKH) en yaygın kronik karaciğer hastalığı türüdür ve metabolik sendromun (MetS) hepatik kanıtıdır. Ancak NAYKH’li hastalar her zaman MetS’ye sahip değildir ve MetS’li tüm hastalar her zaman NAYKH’ye sahip değildir. Çalışmamızda MetS olmayan hastalarda NAYKH ile ilişkili faktörleri araştırmayı amaçladık. Gereç ve Yöntemler: Çalışmamız şehir merkezimizde rastgele seçilen 10 Aile Sağlığı Merkezi’nden (ASM) en az 400 gönüllü ile yapılmıştır. Bireylerden tam kan sayımı, biyokimyasal testler ve hepatobiliyer ultrasonografi (hUSG) yapıldı. Vücut kitle indeksi (BMI), homeostaz Modeli İnsülin Direnci Değerlendirmesi (HOMA-IR), fibrozis-4 (FIB-4) ve BARD skorları hesaplandı. Bulgular: Çalışmada karaciğer yağlanması prevalansı hUSG ile 33,8 % olarak tespit edildi. Karaciğer yağlanması olanlarda (n = 67) evre 1, 2 ve 3 yağlı karaciğer sıklığı sırasıyla 71,6 %, 25,4 % ve 3,0 % olarak bulundu. Tek değişkenli analizde; yağlı karaciğeri olan ve olmayan bireyler arasında yaş, vücut kitle indeksi, bel çevresi, diyastolik kan basıncı, hemoglobin, AST / ALT oranı, ALT, GGT ve trigliserit düzeyleri parametreleri açısından istatistiksel olarak anlamlı farklılıklar vardı. Çok değişkenli lojistik regresyon analizinde, BMI (OR: 1,311, p

🔖

Cite This Article

CANITEZ, V. B., GUNEY, İ., ERKUŞ, E. (2022). Non-Alcoholic Fatty Liver Disease in Patients with Non-Metabolic Syndrome. Batı Karadeniz Tıp Dergisi, Cilt: 5 - Sayı: 2, 143–149. https://ajindex.com/articles/463124

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (13)

Preiss D, Sattar N. Non-alcoholic fatty liver disease: An overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008;115:141-150
Shukla V, Fatima J, Chaudhary S, Ali M, Mishra I. A study of endothelial dysfunction in patients of non-alcoholic fatty liver disease. J Assoc Physicians India 2017;65(9):18-22
Miyaoka Y, Jin D, Tashiro K, Masubuchi S, Ozeki M, Hirokawa F, Hayashi M, Takai S, Uchiyama K. A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high-cholesterol diet. Exp Anim 2018;67(2):239-247
Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med 2017;15(1):45
Streba LA, Vere CC, Rogoveanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: An open question. World J Gastroenterol 2015; 21(14):4103-4110
Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010;42:320-330
Green RM. NASH-hepatic metabolism and not simply the metabolic syndrome. Hepatology 2003;38:14-17
Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev 2017;49(2): 197-211
Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Celia Darland, Finch J, Gastaldelli A, Harrison S, Tio F, Cusi K. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2012;55(5):1389-1397
Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: The insulin resistance atherosclerosis study. Diabetes 1998;47(5):793-800
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7): 412-419
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski MS, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M, APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006. 43(6): 1317-1325
Harrison SA, D Oliver D, H LArnold HL, Gogia S, Neuschwander-